Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||SF1126 + Sorafenib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|SF1126||BRD4 Inhibitor 7 PI3K Inhibitor (Pan) 38||SF1126 is a prodrug of LY294002, a pan PI3K inhibitor with additional activity against BRD4, which potentially results in reduced tumor immunosuppression and inhibits tumor growth (PMID: 23355037, PMID: 27496136, PMID: 31018997).|
|Sorafenib||Nexavar||BAY 43-9006||CSF1R Inhibitor 24 FLT3 Inhibitor 55 KIT Inhibitor 51 PDGFR-beta Inhibitor 13 RAF Inhibitor (Pan) 16 RET Inhibitor 39 VEGFR2 Inhibitor 35||Nexavar (sorafenib) is a multikinase inhibitor with activity against several kinases, including RAF kinases, VEGFR2, VEGFR3, PDGFR-beta, KIT, FLT3, RET, and CSF1R, potentially resulting in decreased tumor growth (PMID: 18445656, PMID: 15466206, PMID: 21517818). Nexavar (sorafenib) is approved for metastatic differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||hepatocellular carcinoma||not applicable||SF1126 + Sorafenib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the combination of SF1126 and Nexavar (sorafenib) was synergistic or additive in inhibiting proliferation of hepatocellular carcinoma cell lines in culture, and demonstrated increased efficacy in hepatocellular carcinoma cell line xenograft models compared to SF1126 alone (PMID: 23355037).||23355037|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|